leisure time -WSS

leisure time

author：explore 2025-09-06 04:42:16 - browse：6

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Stop Congress from blocking public access to science

focus

WSS

Why we need to separate burnout from moral injury in health care

IVG is promising — but it won’t replace IVF quite yet

Setback for rare diseases as Taysha Gene Therapies pulls back

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Colonoscopy at 40? Study finds a possible benefit

Gene therapy has helped boys walk. Can scientists keep it that way?

explore

leisure time

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

The United States is paying nearly triple for new Covid vaccines

What does generative AI mean for health care? We asked experts

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Guidelines to prevent youth baseball injuries need more muscle

Setback for rare diseases as Taysha Gene Therapies pulls back

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

United colonoscopy coverage change 'may cost lives,' doctors say

Colonoscopy at 40? Study finds a possible benefit

explore

European officials brace for rough respiratory virus season

The biotech scorecard for Q4: 16 stock

RSV injection headlines need to be accurate for good uptake

Stop Congress from blocking public access to science

Stop Congress from blocking public access to science

The Karikó problem: Lessons for funding basic research

focus

focus

focus

leisure time